235 related articles for article (PubMed ID: 36428959)
1. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update.
Ferenci P; Reiberger T; Jachs M
Cells; 2022 Nov; 11(22):. PubMed ID: 36428959
[TBL] [Abstract][Full Text] [Related]
2. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
3. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
4. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
6. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
7. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
9. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
10. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
11. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
[TBL] [Abstract][Full Text] [Related]
12. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
13. Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.
Liu H; Zakrzewicz D; Nosol K; Irobalieva RN; Mukherjee S; Bang-Sørensen R; Goldmann N; Kunz S; Rossi L; Kossiakoff AA; Urban S; Glebe D; Geyer J; Locher KP
Nat Commun; 2024 Mar; 15(1):2476. PubMed ID: 38509088
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
[TBL] [Abstract][Full Text] [Related]
15. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
18. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
19. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]